Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF + High-Dose IL-2 in Advanced Melanoma
NCT00616564Phase 2Completed
- Sponsor
- Mount Sinai Medical Center
- Start
- Feb 2006
- Primary completion
- Sep 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in melanoma, sponsored by Mount Sinai Medical Center. Primary endpoints: 1-Year Survival Rate, 2-Year Survival Rate and 1 more. Started Feb 2006; status: completed.
02
Drugs
sargramostim
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00616564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00616564.